That better therapies should result in more patients with higher levels of relief is not surprising, but individual patient analysis has not been done for migraine or neuropathic pain to allow a comparison to be made.
17 19 20 21 Two small cross sectional studies comparing women managed by biopsy and selective recall with those managed by immediate large loop excision found no differences in histological outcomes, 22 23 while one study of women with high grade abnormal cytology suggested immediate large loop excision was associated with lower levels of anxiety after the intervention and higher levels of relief.
Greater discrimination between pain therapies at higher levels of pain relief has been shown previously for acute pain [ 15].
The responder analysis demonstrated that a larger proportion of patients achieved higher levels of pain relief with active treatment than with placebo, and that the absolute difference, illustrated by the NNT, was large, clinically significant, and more discriminatory at higher levels of pain relief.
With placebo and active drugs the proportion achieving higher levels of pain relief increased over time, perhaps due to a natural waning of pain inherent in the "flare" design.
Higher levels of pain relief resulted in higher (worse) NNTs for 5 and 10 mg etoricoxib, while the 30 and 60 mg etoricoxib doses maintained stable and reasonably low (good) NNTs over the range of at least 10% pain relief to at least 70% pain relief (range of NNTs 3.5 to 6.7 for 30 mg, and 2.3 to 3.6 for 60 mg).
Dichotomous responder analysis using higher levels of pain relief of at least 50% over baseline demonstrated an efficacy equivalent to that measured in other pain states, contradicting the idea that that it is time to reconsider the place of drug therapies in arthritis [ 1].
The new relief will be set at a new and higher level of 20%.
Patients desire more than just pain relief, function, and the ability to return to higher level activities after TKA.
The use of narcotics for medicinal pain relief is on the increase but generally has not resulted in a higher level of abuse.
The sumatriptan injectable preparation showed a high level of headache relief from the initial stage of administration, with 60% or greater at 0.5 hours and 80% or more at 1 hour after administration.
